Angiogenesis markers in rheumatoid arthritis

Future Rheumatology

Volumn 3, Issue 2, 2008, Pages 153-159

  Clavel, Gaëlle ^a,b,c   Boissier, Marie Christophe ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

Angiogenesis; Biologics; Experimental models; Inflammation; Monoclonal antibodies; Rheumatoid arthritis; Ultrasonography; Vaccination

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIC PROTEIN; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACENTAL GROWTH FACTOR ANTIBODY; SORAFENIB; SUNITINIB; THROMBOSPONDIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; CARDIOVASCULAR DISEASE; COLON CANCER; DISEASE ACTIVITY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG SYNTHESIS; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYNOVIUM; UNSPECIFIED SIDE EFFECT;

EID: 44149093384     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.2.153     Document Type: Review

References (64)

1. Carmeliet P: Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003).
2. Koch AE, Distler O: Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther. 9(Suppl. 2), S3 (2007).
3. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 94. 794-814 (1999).
4. Shim WS, Ho IA. Wong PE: Angiopoietin: a TIE(d) balance In tumor angiogenesis. Mol. Cancer Res. 5(7), 655-665 (2007).
5. Arsic N, Zentilin L, Zacchigna S et al.: Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol. Ther. 7(4), 450-459 (2003).
6. Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp. Cell Res. 312(5), 630-641 (2006).
7. Khong TL, Larsen H, Raatz Y, Paleolog E: Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 10(4), 243-258 (2007).
8. Lainer-Carr D, Brahn E: Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat. Clin, Pract. Reumatol. 3, 434-442 (2007).
9. Rad FH, le Buanec H. Paturance S et al.: VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl Acad, Sci. USA. 104(8), 2837-2842 (2007).
10. Luttun A, Tjwa M, Carmeliet P: Placental growth factor (P1GF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. NY Acad. Sci. 979, 80-93 (2002).
11. Fischer C, Jonckx B, Mazzone M et al.: Anti-P1GF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3), 463-475 (2007).
12. Costa C, Incio, J, Soares R: Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10(3), 149-166 (2007).
13. Mor F, Quintana FJ, Cohen IR: Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol. 172(7), 4618-4623 (2004).
14. 2! See what HIF can do! Ann. Rheum. Dis. 64(7), 971-980 (2005).
15. Paleolog E: Hypoxia: not merely a regulator of angiogenesis? Arthritis Res. Ther. 6(2), 75-77 (2004).
16. Giatromanolaki A, Sivridis E, Maltezos E et al.: Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 5(4), R193-R201 (2003).
17. Berse B, Hunt JA, Diegel RJ et al.: Hypoxia augments cytokine (transforming growth factor-β (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin. Exp. Immunol. 115(1), 176-182 (1999).
18. Clavel. G. Valvason C, Yarnaoka K et al.: Relationship between angiogenesis and inflammation in experimental arthritis. Eur. Cytokine Netw. 17(3), 202-210 (2006).
19. Hirohata S, Sakakibara J: Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet 353(9161), 1331 (1999).
20. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D: Angiogenesis in rheumatoid arthritis. Histol. Histopathol. 23(5), 557-566 (2006).
21. Koch AE: The role of angiogenesis in rheumatoid arthritis: recent developments. Ann. Rheum. Dis. 59(Suppl. 9), 165-171 (2000).
22. Gravallese E, Pettit A, Lee R et al.: Angiopoletin-1 is expressed in the synovium of patients wih rheumatoid arthritis and is induced by tumour necrosis factor α. Ann. Rheum. Dis. 62, 100-107 (2003).
23. Scott B, Zaratin P, Colombo A, Hansbury M, Winkler J, Jackson J: Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblast. J. Rheumatol. 29(2), 230-239 (2002).
24. DeBusk LM, Chen Y, Nishishita T, Chen J. Thomas JW, Lin PC: Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. 48(9) 2461-2471 (2003).
25. Uchida T. Nakashima M, Hirota Y, Miyazaki Y, Tsukazaki T, Shindo H: Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann. Rheum. Dis. 59(8), 607-614 (2000).
26. Ikeda M, Hosoda Y, Hirose S, Okada Y, Ikeda E: Expression of vascular endothelial growth factor isoforms and their receptors flt-1, KDR, and neuropitin-I in synovial tissues of rheumatoid arthritis. J. Pathol. 191(4), 426-433 (2000).
27. Pettit A, Gravallese E, Manning C el al.: Angiopoietin-1 is expressed in RA synovium and is induced by TNF-α in cultured synovial fibroblasts. Arthritis Rheum. S1845 (2001).
28. Middleton J, Americh L, Gayon R et al.: Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res. Ther. 6, 60-72 (2004).
29. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum. 39,(7), 1082-1091 (1996).
30. Malemud CJ: Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin. Chim. Acta 375(1-2), 10-19 (2007).
31. Clavel G, Bessis N, Boissier MC: Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 70(5), 321-326 (2003).
32. Yamashita A, Yonemitsu Y, Okano S et al.: Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J. Immunol. 168(1), 450-457 (2002).
33. Yoo SA, Bae DG, Ryoo JW et al.: Arginine-rIch anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-α and IL-6 by human monocytes. J. Immunol. 175(9), 5846-5855 (2005).
34. Chen Y, Donnelly E, Kobayashi H. Debusk LM, Lin PC: Gene therapy targeting the Tie2 function ameliorates collagen-incluced arthritis and protects against bone destruction. Arthritis Rheum. 52(5), 1585-1594 (2005).
35. Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J: Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor. PTK787/ ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm. Res. 53(4), 133-142 (2004).
36. Takahashi H. Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T: Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin. Exp. Rheumatol. 23(4), 455-461 (2005).
37. Rico MC, Castaneda JL, Manns JM et al.: Amelioration of inflammation, angiogenesis and CTGF expression in an arthritis model by a TSP1-derived peptide treatment. J. Cell Physiol. 211(2), 504-512 (2007).
38. Ballara S, Taylor P, Reusch P et al.: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44(9), 2055-2064 (2001).
39. Clavel G, Bessis N, Lemeiter D et al.: Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin. Immunol. 124(2), 158-164 (2007).
40. Lee S, Joo Y. Kim W et al.: Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 19(3), 321-324 (2001).
41. Sone H, Sakauchi M, Takahashi A et al.: Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis. Correlation with disease activity. Life Sci. 69(16), 1861-1869 (2001).
42. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M: A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin. Rheumatol. 25(3), 314-319 (2006).
43. Nagashima M, Wauke K, Hirano D et al.: Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 39(11), 1255-1262 (2000).
44. Aggarwal A, Panda S, Misra R: Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. Ann. Rheum. Dis. 63(7), 891-892 (2004).
45. Strunk J. Bundke E, Lange U: Anti-TNF-α antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol. Int. 26(3), 252-256 (2006).
46. Canete JD, Pablos JL, Sanmarti R et al.: Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 50(5), 1636-1641 (2004).
47. Walsh DA: Angiogenesis and arthritis. Rheumatology 38(2), 103-112 (1999).
48. Kucharz EJ, Gozdzik J, Kopec M et al.: A single infusion of infliximab increases the serum enclostatin level in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 21(2), 273-274 (2003).
49. Taylor PC: Serum vascular markers and vascular imaging in assessmeni of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford). 44(6), 721-728 (2005).
50. Veale DJ, Fearon U: Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract. Res. Clin. Rheumatol. 20(5), 941-947 (2006).
51. Han SW, Kim GW, Seo JS et al.: VEGF gene polymorphisms and susceptibility to rheumatoid arthritis. Rheumatology (Oxford). 43(9), 1173-1177 (2004).
52. Rueda B, Gonzalez-Gay MA, Lopez-Nevot MA et al.: Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid athritis. Hum. Immunol. 66(8), 864-868 (2005).
53. Butt C, Lim S. Greenwood C, Rahman P: VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriapc arthritis. BMC Musculoskelet. Disord. 8, 1 (2007).
54. Vaudo G, Marchesi S, Gerli R et al.: Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann. Rheum. Dis. 63(1), 31-35 (2004).
55. Cardillo C, Schinzari F, Mores N et al.: Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin. Pharmacol. Ther. 80(3), 275-281 (2006).
56. Gonzalez-Gay MA, Garcia-Unzueta MT, de Matias JM et al.: Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24(4). 373-379 (2006).
57. Maki-Petaja KM, Hall FC. Booth AD et al.: Rheumatoid arthritis is associated with Increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114(11), 1185-1192 (2006).
58. Grisar J, Aletaha D, Steiner CW et al.: Endothetial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann. Rheum. Dis. 66(10), 1284-1288 (2007).
59. Steuer A, Blomley M, Cosgrove D, Maini R, Taylor P: Combined power colour Doppler and greyscale ultrasound demonstrate an association between vascularity and erosion in rheumatoid arthritis. Arthritis Rheum. S292 (2000).
60. Szkudlarek M, Narvestad E. Klarlund M, Court-Payen M, Thomsen HS, Ostergaard M: Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum. 50(7), 2103-2112 (2004).
61. Giovagnorio F, Martinoli C, Coarl G: Power Doppler sonography in knee arthritis - a pilot study. Rheumatol. Int. 20(3), 101-104 (2001).
62. Taylor PC, Steuer A, Gruber J et al.: Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 50(4), 1107-1116 (2004).
63. Taylor PC, Steuer A, Gruber J et al.: Ultrasonographic and radiographic results, from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 54(1), 47-53 (2006).
64. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W: Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann. Rheum. Dis. 65(11), 1433-1437 (2006).